熱門資訊> 正文

展望眼用贝伐单抗治疗干性AMD获得批准

2026-07-25 03:20

The US FDA has approved Outlook Therapeutics' (OTLK) Lytenava (bevacizumab-vikg) for wet AMD.
Lytevana is the first ophthalmic bevacizumab approved for the condition. It is expected to launch by the end of the year.
The standard formulation of bevacizumab is marketed by Roche (RHHBY) as Avastin.
The drug is administered once a month.

More on Outlook Therapeutics

Outlook Therapeutics Heads Into Another FDA PDUFA Decision For Lytenava
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity
Outlook gains as wet AMD therapy reconsidered for FDA review
Outlook Therapeutics prices $5M registered direct offering
Seeking Alpha’s Quant Rating on Outlook Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。